Inhibition and mechanism on combination of recombinant human endostatin and cisplatin in mouse model bearing S180 tumor ascite

Chinese Journal of Cancer Prevention and Treatment

Volumn 22, Issue 6, 2015, Pages 442-446

  Wei, Hong Mei ^a   Qin, Shu Kui ^b   Yin, Xiao Jin ^c   Chen, Ya Li ^c   Hua, Hai Qing ^b   Wang, Lin ^b   Yang, Ning Rong ^b   Chen, Ying Xia ^b   Liu, Xiu Feng ^b  

^a QINGDAO CENTRAL HOSPITAL   (China)

^b No 81 Hospital of PLA   (China)

^c Jiangsu Simcere Pharmaceutical Research Institute   (China)

Author keywords

Ascite; Cisplatin; Matrix metalloproteinases 2(MMP 2); Peritoneum permeability; Recombinant human endostatin; Vascular endothelial growth factor(VEGF)

Indexed keywords

CISPLATIN; GELATINASE A; RECOMBINANT ENDOSTATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES TUMOR; BODY MASS; CANCER INHIBITION; CELL PERMEABILIZATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE; FLOW CYTOMETRY; KIDNEY FUNCTION; LIVER FUNCTION; MOUSE; NONHUMAN; PERITONEUM; PROTEIN ANALYSIS; SURVIVAL TIME; TUMOR CELL; TUMOR VOLUME;

EID: 84928381312     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hou W, Sanyal AJ. Ascites: diagnosis and management[J]. Med Clin North Am, 2009, 93(4): 801-817.
2. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment[J]. Eur J Cancer, 2006, 42(5): 589-597.
3. Chen X, Liu Y, Yin Y, et al. Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma[J]. J Chemother, 2012, 24(4): 231-236.
4. Xue SL, Deng X, Liu Y, et al. Intraperitoneal recombinant human endostatin combined with chemotherapy for refractory malignant ascites due to gastrointestinal cancer: a pilot study[J]. Hepatogastroenterology, 2013, 60(121): 118-123.
5. Zhao J, Chen X, Zhang A, et al. A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer[J]. Med Oncol, 2014, 31(4): 930-940.
6. Kitamura K, Kubota K, Ando M, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion[J]. Cancer Chemother Pharmacol, 2013, 71(2): 457-461.
7. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites[J]. Eur J Surg Oncol, 1997, 23(6): 526-531.
8. Zhou Y, Wen F, Zhang P, et al. Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation[J]. Cancer Gene Ther, 2013, 20(3): 178-185.
9. Han Q, Fu Y, Zhou H, et al. Contributions of Zn(II)-binding to the structural stability of endostatin[J]. FEBS, 2007, 581(16): 3027-3032.
10. Jia H, Kling J. China offers alternative gateway for experimental drugs[J]. Nat Biotechnol, 2006, 24(2): 117-118.
11. Jiang ZY, Qin SK, Yin XJ, et al. Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model[J]. Exp Ther Med, 2012, 4(2): 277-284.
12. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients[J]. Clin Biochem, 2004, 37(5): 363-369.
13. Hirayama N, Tabata C, Tabata R, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma[J]. Respir Med, 2011, 105(1): 137-142.
14. Cheng D, Liang B, Kong H. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites[J]. Med Oncol, 2012, 29(2): 1397-1402.
15. Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion[J]. Curr Oncol Rep, 2013, 15(3): 207-216.
16. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP-2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation[J]. Cancer Res, 2003, 63(17): 5224-5229.